| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | Q747Y6TT42 |
| InChI Key | PMJIHLSCWIDGMD-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C19H14N2O2S |
| Molecular Weight | 334.4 |
| AlogP | 3.26 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 0.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 44.0 |
| Molecular species | None |
| Aromatic Rings | 4.0 |
| Heavy Atoms | 24.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Glycogen synthase kinase-3 beta inhibitor | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Kinase
Protein Kinase
CMGC protein kinase group
CMGC protein kinase GSK family
|
- | 5-2000 | - | - | - | |
|
Enzyme
Protease
Cysteine protease
|
- | 600-5900 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Alzheimer Disease | 2 | D000544 | ClinicalTrials |
| Child Development Disorders, Pervasive | 2 | D002659 | ClinicalTrials |
| Myotonic Dystrophy | 2 | D009223 | ClinicalTrials |
| Resources | Reference |
|---|---|
| ChEBI | 147398 |
| ChEMBL | CHEMBL3545157 |
| DrugBank | DB12129 |
| EPA CompTox | DTXSID90235682 |
| FDA SRS | Q747Y6TT42 |
| Guide to Pharmacology | 6929 |
| SureChEMBL | SCHEMBL676929 |
| ZINC | ZINC000013985228 |